| pubmed-article:15126875 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15126875 | lifeskim:mentions | umls-concept:C0021083 | lld:lifeskim |
| pubmed-article:15126875 | lifeskim:mentions | umls-concept:C0007134 | lld:lifeskim |
| pubmed-article:15126875 | lifeskim:mentions | umls-concept:C0003320 | lld:lifeskim |
| pubmed-article:15126875 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:15126875 | lifeskim:mentions | umls-concept:C0205369 | lld:lifeskim |
| pubmed-article:15126875 | lifeskim:mentions | umls-concept:C0521115 | lld:lifeskim |
| pubmed-article:15126875 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:15126875 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:15126875 | pubmed:issue | 6 Pt 1 | lld:pubmed |
| pubmed-article:15126875 | pubmed:dateCreated | 2004-5-5 | lld:pubmed |
| pubmed-article:15126875 | pubmed:abstractText | The activation of antigen specific T cells by tumor associated antigens (TAA) might be a promising treatment strategy for patients with renal cell carcinoma (RCC). We analyzed TAA expression in patients with RCC as well as the prevalence of fitting HLA phenotypes and calculated the percent of patients eligible for peptide vaccination trials. | lld:pubmed |
| pubmed-article:15126875 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15126875 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15126875 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:15126875 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15126875 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15126875 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:15126875 | pubmed:issn | 0022-5347 | lld:pubmed |
| pubmed-article:15126875 | pubmed:author | pubmed-author:SchmittMichae... | lld:pubmed |
| pubmed-article:15126875 | pubmed:author | pubmed-author:GschwendJürge... | lld:pubmed |
| pubmed-article:15126875 | pubmed:author | pubmed-author:MüllerCarlhei... | lld:pubmed |
| pubmed-article:15126875 | pubmed:author | pubmed-author:GreinerJochen... | lld:pubmed |
| pubmed-article:15126875 | pubmed:author | pubmed-author:RinghofferMar... | lld:pubmed |
| pubmed-article:15126875 | pubmed:author | pubmed-author:SchenkArianeA | lld:pubmed |
| pubmed-article:15126875 | pubmed:author | pubmed-author:KirscheHanspe... | lld:pubmed |
| pubmed-article:15126875 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15126875 | pubmed:volume | 171 | lld:pubmed |
| pubmed-article:15126875 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15126875 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15126875 | pubmed:pagination | 2456-60 | lld:pubmed |
| pubmed-article:15126875 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15126875 | pubmed:meshHeading | pubmed-meshheading:15126875... | lld:pubmed |
| pubmed-article:15126875 | pubmed:meshHeading | pubmed-meshheading:15126875... | lld:pubmed |
| pubmed-article:15126875 | pubmed:meshHeading | pubmed-meshheading:15126875... | lld:pubmed |
| pubmed-article:15126875 | pubmed:meshHeading | pubmed-meshheading:15126875... | lld:pubmed |
| pubmed-article:15126875 | pubmed:meshHeading | pubmed-meshheading:15126875... | lld:pubmed |
| pubmed-article:15126875 | pubmed:meshHeading | pubmed-meshheading:15126875... | lld:pubmed |
| pubmed-article:15126875 | pubmed:meshHeading | pubmed-meshheading:15126875... | lld:pubmed |
| pubmed-article:15126875 | pubmed:meshHeading | pubmed-meshheading:15126875... | lld:pubmed |
| pubmed-article:15126875 | pubmed:meshHeading | pubmed-meshheading:15126875... | lld:pubmed |
| pubmed-article:15126875 | pubmed:meshHeading | pubmed-meshheading:15126875... | lld:pubmed |
| pubmed-article:15126875 | pubmed:meshHeading | pubmed-meshheading:15126875... | lld:pubmed |
| pubmed-article:15126875 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15126875 | pubmed:articleTitle | Simultaneous expression of T-cell activating antigens in renal cell carcinoma: implications for specific immunotherapy. | lld:pubmed |
| pubmed-article:15126875 | pubmed:affiliation | Departments of Internal Medicine III, University Hospital and German National Bone Marrow Donor Registry, Ulm, Germany. | lld:pubmed |
| pubmed-article:15126875 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15126875 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
